Initiation and Management of Donepezil and Memantine for Dementia

Donepezil Initiation and Efficacy

The American College of Physicians recommends donepezil for mild to moderate Alzheimer's disease, showing statistically significant improvement in cognition and global function compared to placebo 1, 4
Donepezil is indicated for mild to moderate Alzheimer's disease, with a recommended starting dose of 5mg once daily in the morning, and consideration of increasing to 10mg daily after 4 weeks if well tolerated 5, 6
Donepezil shows consistent treatment effects for improvement in cognitive function across all severity levels of Alzheimer's disease except mild cognitive impairment 1, 7
Donepezil also shows significant benefits in vascular dementia, though effects are smaller than in Alzheimer's disease 1, 2
The strength of evidence for donepezil's efficacy in mild to moderate Alzheimer's disease is high, with multiple studies demonstrating statistically significant improvements in cognition and global function 1, 4

No cited facts are available for memantine initiation and efficacy, as all relevant information is marked as [ignore ref]

Neither donepezil nor memantine achieves the 4-point change in ADAS-cog considered clinically significant, though statistically significant improvements occur 1, 2
Benefits on cognitive function, activities of daily living, and behavior can be maintained for approximately 21 to 81 weeks with donepezil 10mg/day, although the exact duration of benefit is not well established 1, 2

Monitor for gastrointestinal side effects with donepezil, particularly nausea and vomiting (relative risk 2.54), diarrhea (relative risk 2.57), and anorexia (relative risk 3.21), which are dose-dependent and more common at 10mg versus 5mg 6
Initial increase in agitation may occur with donepezil but typically subsides after the first few weeks 6

Prescribing donepezil for mild cognitive impairment is not recommended, as evidence shows no significant benefit 1, 2
Starting at high doses of donepezil is not recommended, as gradual titration improves tolerability 6
Administering donepezil at bedtime rather than morning increases the risk of sleep disturbances 5
Expecting dramatic clinical improvement from donepezil or memantine is not realistic, as effects are statistically significant but modest in magnitude 3